Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

Description

The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of non-invasive screening tests for CAD AFTER waitlist activation is not inferior to regular (i.e., annual) screening for CAD during wait-listing for the prevention of Major Adverse Cardiac Events. Secondary analyses will assess the impact of screening on the rate of transplantation, and the relative cost-effectiveness of screening.

Conditions

Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication

Talk to us

Study Overview

On this page

Study Details

Study overview

The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of non-invasive screening tests for CAD AFTER waitlist activation is not inferior to regular (i.e., annual) screening for CAD during wait-listing for the prevention of Major Adverse Cardiac Events. Secondary analyses will assess the impact of screening on the rate of transplantation, and the relative cost-effectiveness of screening.

Canadian-Australasian Randomised Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease

Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

Condition
Cardiovascular Diseases
Intervention / Treatment

-

Contacts and Locations

Tucson

University of Arizona, Tucson, Arizona, United States, 85724

Washington

The George Washington University, Washington, District of Columbia, United States, 20052

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. adults aged 18 years of age or older
  • 2. Dialysis-dependent kidney failure and currently being assessed for OR active on the kidney transplant waiting list
  • 3. expected to require further screening for CAD prior to transplantation (by current standard of care);
  • 4. able to give consent;
  • 5. anticipated to undergo transplantation more than 12 months from date of enrolment
  • 1. patients with signs or symptoms suggestive of uncontrolled cardiac disease such as unstable coronary syndromes, decompensated heart failure, uncontrolled arrhythmia, and severe valvular heart disease;
  • 2. patients who "on-hold" for transplantation due to a medical problem;
  • 3. patients with other solid organ transplants;
  • 4. multi-organ transplant candidates (e.g. kidney-pancreas transplant candidates);
  • 5. patients with planned living donor transplant;
  • 6. patients unable to give consent.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of British Columbia,

Jagbir Gill, MD, PRINCIPAL_INVESTIGATOR, University of British Columbia

Study Record Dates

2025-12-31